Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy
(MedPage Today) -- PHILADELPHIA -- Sparsentan (Filspari) outperformed irbesartan in patients with IgA nephropathy over the 2-year phase III PROTECT trial.
Over a 110-week treatment period, those on sparsentan had an average 42.8% (95% CI -49...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news
More News: Avapro | Urology & Nephrology